32 results about "Vancomycin-resistant Enterococcus" patented technology

Disclosed are synthesized derivatives of a natural product, (±)-marinopyrrole A, shown as structural formula I, which have inhibition activities on gram-positive bacteria, such as methicillin sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), oxacilline-resistant Staphylococcus aureus (ORSA), methicillin-resistant Staphylococcus epidermidis (MRSE) and the like. Furthermore, the methods for preparing (±)-marinopyrrole A and the derivatives thereof are disclosed. According to the study of antibacterial activity in vitro, the synthesized derivatives of the natural product (±)-marinopyrrole A have excellent antibiotic activities on the gram-positive bacteria, such as methicillin sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), oxacilline-resistant Staphylococcus aureus (ORSA), methicillin-resistant Staphylococcus epidermidis (MRSE) and the like, and have potential prospects in clinical application.

Disclosed are an anti-methicillin-resistant Staphylococcus aureus agent (an anti-MRSA agent) and an anti-vancomycin-resistant Enterococcus agent (an anti-VRE agent), each of which comprises, as an active ingredient, an Macaranga tanarius extract that is extracted from a plant Macaranga tanarius with an extraction solvent comprising at least an organic solvent. Alternatively, each of the anti-MRSA agent and the anti-VRE agent may comprise at least one member selected from nymphaeol-A, nymphaeol-B and nymphaeol-C as an active ingredient.

The invention belongs to the technical field of medicinal chemistry, and discloses quatemary ammonium chalcone derivatives resistant to drug-resistance bacteria activities, a preparation method and application of the quatemary ammonium chalcone derivatives. A structural formula is as shown in the description. Proved by invitro antibacterial activity experiments and erythrocyte hemolytic experiments, a large part of compounds in the series of the derivatives have great antibacterial effects and selections on staphylococcus aureus and colonic enterococcus faecalis of gram-positive bacteria, escherichia coli and pseudomonas aeruginosa of gram-negative bacteria. The selected part of compounds show great antimicrobial activities on a plurality of 'superbacteria' including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), carbapenem-resistant enterobacteriaceae (CRE) and new delhi metallo (NDM) carrying NDM genes, and especially show excellent activities on the MRSA. Proved by invitro erythrocyte toxicity experiments, the series of compounds are low in erythrocyte toxicity and can be adopted as new anti-microbial drug candidates.

The invention belongs to the technical field of biomedicine, and relates to a gene for mediating drug resistance of vancomycin and application thereof. The drug-resistant gene has a nucleotide sequence of SET ID.1, and protein encoded by the gene has an amino acid sequence of SEQ ID.2. The obtained gene sequence is a novel drug-resistance deciding gene of vancomycin resistant Enterococcus, and can prepare probe sequences of PCR amplification and gene microarray diagnostic probes for clinical diagnosis of resisting infection of the vncomycin resistant Enterococcus. The invention provides a novel detection target of drug-resistant strains for clinical practice, and provides a method for detecting Enterococcus carrying novel vancomycin resistance gene by Real-time PCR and a method for detecting the Enterococcus carrying the novel vancomycin resistance gene by a gene microarray; and the detection methods have the advantages of quickness, accuracy, simple and convenient operation, and the like.

The invention belongs to the field of medicinal chemistry, and discloses a dialkyl cationic amphiphilic antibacterial peptide analogue with antibacterial activity and a synthesis method thereof. Through four-step reaction, a target product can be simply and fast obtained. A major structure is shown as the accompanying drawing. In-vitro antibacterial activity experiments prove that the most compounds in the series show good antibacterial effects on staphylococcus aureus and escherichia coli; partial compounds show excellent antibacterial activity on super bacteria including MRSA (methicillin-resistance staphylococcus aureus), VRE (vancomycin-resistant enterococcus) and CRE (carbapenemase enterobacteriaceae). In-vitro red cell toxicity experiments also show the series of compounds have low red cell toxicity, so that the series of compounds are hopeful to be used as novel antibacterial candidate medicine. The formulas are shown in the description.

The invention relates to application of cinnamaldehyde in preparation of drugs for targeted therapy of bacterial infection, and belongs to the technical field of medicines. Bacteria are multi-drug-resistant bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant baumanii, carbapenem-resistant enterobacteriaceae, carbapenem-resistant pseudomonas aeruginosa or vancomycin-resistant enterococcus. By the research result of the invention, an efficient, low-toxicity and novel antibacterial medicine which is used for targeted therapy of multi-drug-resistant bacterial infection is provided for bacterial infection of departments such as a clinical pneumology department, a hematology department, an emergency treatment ICU, an oncology department and organ grafting, in-vivo pharmacodynamics, an action mechanism and a theoretical experiment basis are provided for research and development of traditional Chinese medicines for treating multi-drug-resistant bacterial infection, and conditions are created for transformation of scientific achievements.